Evidence map›Paper›PMID 27713276›Full record

ReviewPharmaceuticals (Basel, Switzerland)2010

Theophylline.

Peter J Barnes

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04789499 phase2completednot on this mapstarted 2021, after this paper: background citation

Smell in Covid-19 and Efficacy of Nasal Theophylline

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2021Enrolled51ConditionsCovid19, Anosmia, Olfactory Disorder, Covid-19 PandemicArmsTheophylline Powder, Placebo Comparator
NCT05216614 phase2withdrawnnot on this mapstarted 2021, after this paper: background citation

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2022Enrolled0ConditionsCOVID-19, Olfactory Disorder, ParosmiaArmsFluvoxamine, Placebo
NCT05947643 phase2completednot on this mapstarted 2022, after this paper: background citation

Smell in COVID-19 and Efficacy of Nasal Theophylline 3

TypeinterventionalSponsorWashington University School of MedicineRan2022 to 2025Enrolled77ConditionsCOVID-19Armstheophylline, Placebo
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 112 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. APurinergic signalling · 2025
    Review
  12. Treatment of lung diseasesMaterials today. Bio · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Peter J BarnesNational Heart and Lung Institute, Imperial College, London, UK. p.j.barnes@imperial.ac.uk.
Imperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theophylline (3-methyxanthine) has been used to treat airway diseases for over 70 years. It was originally used as a bronchodilator but the relatively high doses required are associated with frequent side effects, so its use declined as inhaled β₂-agonists became more widely used. More recently it has been shown to have anti-inflammatory effects in asthma and COPD at lower concentrations. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes. Through this mechanism theophylline also reverses corticosteroid resistance and this may be of particular value in severe asthma and COPD where HDAC2 activity is markedly reduced. Theophylline is given systemically (orally as slow-release preparations for chronic treatment and intravenously for acute exacerbations of asthma) and blood concentrations are determined mainly by hepatic metabolism, which may be increased or decreased in several diseases and by concomitant drug therapy. Theophylline is now usually used as an add-on therapy in asthma patients not well controlled on inhaled corticosteroids and in COPD patients with severe disease not controlled by bronchodilator therapy. Side effects are related to plasma concentrations and include nausea, vomiting and headaches due to PDE inhibition and at higher concentrations to cardiac arrhythmias and seizures due to adenosine A₁-receptor antagonism.

Indexed as

adenosine receptorbronchodilatationdrug interactionhistone deacetylaseimmunomodulationinflammationmethylxanthinephosphodiesteraseplasma concentration

Identifiers

PMID27713276
PMCPMC4033977
OpenAlexW4211059693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.